Henagliflozin–metformin extended-release versus metformin for newly diagnosed type 2 diabetes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicenter, randomized, phase 4 study will enroll 268 adults with new-onset type 2 diabetes and randomly assign them 1:1 to either henagliflozin–metformin extended-release (5 mg/500 mg once daily) plus lifestyle intervention or metformin (500 mg twice daily) plus lifestyle intervention. The primary endpoint is change in glycated hemoglobin (HbA1c) from baseline at 24 weeks, with secondary outcomes including fasting and postprandial glucose, body weight, metabolic parameters, diabetes remission rate, and safety assessments. Eligible participants are 18–75 years old with disease duration ≤24 months, HbA1c 7.0–9.0%, fasting venous glucose ≤11.1 mmol/L, BMI ≥18.5 kg/m2, and no prior use of hypoglycemic drugs. The trial is led by Zhejiang Provincial People's Hospital with pharmaceutical collaboration and is intended to provide evidence on early combination therapy in newly diagnosed patients.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Age between 18 and 75 years old.
* Diagnosed with type 2 diabetes according to WHO diagnostic criteria, with HbA1c between 7% and 9% at this examination, fasting venous blood glucose ≤ 11.1 mmol/L, and BMI ≥ 18.5 kg/m2; known disease duration ≤ 24 months.
* Voluntary participation in this study and signing of the informed consent form. If the subject is unable to read the informed consent form (e.g., illiterate subjects), a witness must be present to observe the informed consent process and sign the informed consent form on their behalf.
* No previous use of hypoglycemic drugs.

Exclusion Criteria:

* Type 1 diabetes.
* Participants who have participated in other clinical trials of diabetes treatment drugs before the start of this study.
* Those who have experienced diabetic ketoacidosis, diabetic lactic acidosis or hyperosmolar non-ketotic coma within the past six months and required hospitalization.
* Those who have experienced decompensated heart failure (NYHA class III and IV), unstable angina, stroke or transient ischemic attack, myocardial infarction, severe arrhythmia, undergone cardiac surgery or vascular reconstruction (including coronary artery bypass grafting or percutaneous coronary intervention) within the past six months.
* Those taking glucocorticoid drugs (excluding topical or inhaled medications).
* Those with a life expectancy of less than one year due to malignant tumors, active tuberculosis, or acute infections.
* Those with clinically significant urinary tract or genital infections, or a history of recurrent urinary tract or genital infections.
* Those with a history of hypertension whose blood pressure has not been effectively controlled despite antihypertensive drug treatment: systolic blood pressure (SBP) \> 160 mmHg and/or diastolic blood pressure (DBP) \> 100 mmHg.
* Those with liver and kidney function indicators meeting the following criteria: alanine aminotransferase (ALT) and/or aspartate aminotransferase (AST) ≥ 3.0×ULN; estimated glomerular filtration rate (eGFR) \< 45 ml/min/1.73 m² (calculated according to the Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula).
* Those allergic to the investigational drug or its components.
* Pregnant or lactating women and those with the intention to conceive within three months of the last dose.
* Other patients deemed unsuitable for participation in this clinical trial by the investigator.

Where it's running

• Zhejiang Provincial People's Hospital
  Hangzhou, Zhejiang, China Recruiting

Study contacts

• Study coordinator: Xiaohong Wu
• Email: drxhwu@163.com
• Phone: +86-13815870351

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Predicting diabetes outcomes after a kidney transplant

  This project will try to see if whole genome sequencing can help predict outcomes for adults who develop new diabetes after a kidney transplant.

  Recruiting Fondazione Policlinico Universitario Agostino Gemelli IRCCS · Roma · NCT07512804

• Assessing stroke risk in patients with newly diagnosed atrial fibrillation

  This study is testing how to identify stroke risk in people who have just been diagnosed with atrial fibrillation to see who might need blood-thinning medication to prevent strokes.

  Recruiting University of Southern Denmark · Esbjerg, Region Syddanmark · NCT06949319

• Investigating the effects of Empagliflozin on heart function after unexplained strokes

  This study is testing if the medication Empagliflozin can help improve heart function and prevent future strokes in people who have had unexplained strokes.

  Recruiting Phase 2/3 University of East Anglia · Cambridge, Cambridgeshire · NCT06715449

• Short-term treatment with amiodarone for new atrial fibrillation after heart surgery

  This study is testing whether a short-term treatment with amiodarone can help people who develop new atrial fibrillation after heart surgery feel better and keep their heart rhythm stable.

  Recruiting at 2 sites Phase 3 Population Health Research Institute · Hamilton, Ontario and 1 other locations · NCT05841056

• Understanding new-onset atrial fibrillation in patients with heart attacks

  This study is trying to see how new-onset atrial fibrillation affects heart attack patients and if it can help guide their treatment after they leave the hospital.

  Recruiting at 5 sites Shanghai 10th People's Hospital · Kaifeng, Henan and 4 other locations · NCT04528511

• Mapping the causes of new-onset atrial fibrillation after heart surgery

  This study is trying to find out where new heart rhythm problems start in patients who develop them after heart surgery, to help figure out how to prevent them in the future.

  Recruiting at 2 sites University Hospital, Basel, Switzerland · Sankt Pölten and 1 other locations · NCT04964765

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.